Intimation for Press Release of Audited Financial Results (Standalone and Consolidated) for the Quarter and Year ended March 31, 2026.
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anlon Healthcare reported strong FY26 results with consolidated total income of ₹172.22 Cr, up 43% from ₹120.46 Cr in FY25. EBITDA grew 48% to ₹47.77 Cr while PAT increased 42% to ₹29.09 Cr. Standalone figures showed total income of ₹176.26 Cr, EBITDA of ₹46.39 Cr, and PAT of ₹27.81 Cr. Key strategic developments include the acquisition of Bizotic Lifescience as a subsidiary, strengthening of Apiqo Organics for backward integration, and ongoing CDMO projects with 3 molecules under development for 2 global innovator companies. The company serves pharmaceutical, nutraceutical, veterinary, and personal care sectors across 15+ countries.
Strong growth metrics indicate operational strength and successful execution of expansion strategy. Shareholders should note the strategic acquisitions and CDMO pipeline that support management's guidance of approximately 30% revenue CAGR over the next three years.